Home » Takara Bio, MolMed Conclude R&D Agreement for HIV Treatment
Takara Bio, MolMed Conclude R&D Agreement for HIV Treatment
Takara Bio has signed a research and development agreement with MolMed S.p.A., an Italian company specialized in gene therapy treatments. Under the terms of the agreement, the two companies will develop a gene therapy treatment for AIDS. The partners plan to develop an HIV-1 derived lentivirus vector and subsequently establish a method to introduce the vector with therapeutic genes into hematopoietic stem cells of AIDS patients.
Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=9778)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May